Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Fig. 1

Flow chart of the study. HR+/HER2-, Hormone receptor-positive and Human epidermal growth factor receptor 2 negative; ET, Endocrine therapy; EBC, Early breast cancer; Meno, Menopausal status; Pre, Premenopausal status; SERD, Selective estrogen receptor degrader; AI, Aromatase inhibitor; SERM, Selective estrogen receptor modulator; PR, Partial response; SD, Stable disease; PD, Progressive disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us